Skip to main content
OpenTrials
Completed

NCT Number: NCT01161082

Ascending Multi-dose Study of REGN727(SAR236553) With and Without Concomitant Atorvastatin

This study will test the safety, tolerability, and bioeffects (how the body reacts to the drug) of REGN727 compared with placebo (an inactive substance that contains no medicine) in hyperlipidemic patients with or without atorvastatin therapy. The study drug and placebo will be administered by subcutaneous injection at the clinic. There will be a total of 2 or 3 study drug injections over 16 clinic visits, which will include 3 overnight stays(study duration 148 days, not including the screening period). Patients on atorvastatin will take their daily dose in the morning for the duration of the study. Patients will be monitored by the study staff for side effects and the body's response to the study drug. Vital signs(blood pressure, temperature, breathing and heart rate) will be checked, and blood and urine samples will be collected at some or all visits.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hypercholesterolemia Dyslipidemias Hyperlipidemias Lipid Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Site 1, Cincinnati, Ohio, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Men and women with elevated cholesterol on stable doses of atorvastatin 10-40mg/day regimen
  • Body mass index between 18.0 and 35.0 kg/m2, inclusive
  • For women of childbearing potential, a negative serum pregnancy test at the screening visit and a negative urine pregnancy test on day -2 or day -1
  • For men and women of childbearing potential, willingness to utilize adequate contraception and not become pregnant (or have their partner[s] become pregnant)during the full duration of the study
  • Willing, committed and able to return for all the clinic visits and complete all study-related procedures
  • Able to read, and able to sign the informed consent form

Exclusion criteria

  • History of MI, ACS, Angina, Stroke, peripheral vascular disease, or cardiac revascularization
  • Pregnant or breast-feeding women
  • Blood donation of any volume within 1 month prior to administration of study drug
  • Congestive heart failure
  • Consumption of greater than 1 quart of grapefruit juice per day
  • Previous exposure to any therapeutic or investigational biological agent within 30 days of screening
  • History of alcohol or drug abuse within one year to the screening visit

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Treatment and study plan

REGN727(SAR236553)

Drug

subcutaneous

Primary outcomes

  1. The primary endpoint in the study is to assess the incidence and severity of treatment-emergent adverse events in hyperlipidemic patients treated with REGN727 or placebo receiving stable doses of atorvastatin.

    Time frame: visit 4 (day 1) to visit 16 (day 148)

Secondary outcomes

  1. To assess the pharmacodynamic effect of REGN727 added to atorvastatin on lipids

    Time frame: Visit 4 (Day 1) to Visit 16 (Day 148)

  2. To assess the pharmacodynamic effect of monotherapy REGN727 in hyperlipidemic patients

    Time frame: Visit 4 (Day 1) to Visit 16 (Day 148)

  3. To assess the pharmacokinetics of REGN727 in hyperlipidemic patients with or without atorvastatin

    Time frame: Visit 4 (Day 1) to Visit 16 (Day 148)

Sponsors and collaborators

Lead sponsor

Regeneron Pharmaceuticals

Industry

Collaborators

  • Sanofi

Registry information

Official study title

A Randomized, Double-Blind, Placebo-Controlled, Ascending Single to Multi-Dose Study of Safety, Tolerability, and Bioeffect of Subcutaneously Administered REGN727 in Patients With and Without Concomitant Atorvastatin

Important dates

Study start
2010
Primary completion
2011
Study completion
2011
First posted
Jul 13, 2010
Registry last updated
Jan 27, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.